Bafna Pharmaceuticals share news, announcements and annual reports
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Bafna Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008 on BSE, Apr 2018 on NSE
Last close ₹447.90down ₹9.10 (1.99%)BSE ₹447.90
Share price at the NSE close on 30 Oct 2026. Previous close ₹457.00.
30 Oct: open ₹457.00, high ₹457.00, low ₹447.90
52-week range of traded prices to 30 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,060 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 136.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 11.02
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 7,963
Bafna Pharmaceuticals board and management
38 filed, newest first.
Sep 2025
19 Sep · Management
Aug 2025
12 Aug · Management
Jun 2025
Apr 2025
1 Apr · Management
1 Apr · Management
Sep 2024
25 Sep · Management
Sep 2023
26 Sep · Management
Jan 2023
Aug 2022
Mar 2022
Nov 2020
Sep 2020
Jun 2020
Feb 2019
Sep 2018
May 2018
Nov 2017
Oct 2017
6 Oct · Management
Jun 2016
Mar 2016
3 Mar · Management
Mr. M. R. Ramachandran, Chief Financial Officer has submitted his resignation and relieved from the services of the Company effective from ....
May 2015
30 May · Management
Mar 2015
Oct 2014
29 Oct · Management
Mr. R. S. Gowdhaman is appointed as the Company Secretary & Compliance Officer with effect from October 15, 2014 in place of Mr. K. Premnath who has resigned from the service of the Company.
May 2013
21 May · Management
Board of Directors of the Company at its meeting held on May 20, 2013 has approved the re-appointment of Mr. Bafna Mahaveer Chand as Chairman & Managing Director and Mr. Paras Bafna as Whole Time Director.2 May · Management
Vide letter dated May 02, 2013 that the Company has appointed M/s Minepro Communications for marketing serviecs. The Company had entered into agreement with M/s. Minepro Communications for marketing services which include advertising and publicity. The Company further confirms that : 1. The above Company for any of their associates have any shareholding in the Company. 2. None of the person from the above media companies appointed any nominee Director on the Board of the Company; or, 3. There is no management control or any potential conflict of interest arising out of these agreements. 4. Except as provided hereinabove, the Company has not entered into any other back to back treaties / contracts / agreements / MoUs or similar instruments with media companies and / or their associates for the purpose of advertising publicity etc.2 May · Management
Company had entered into agreement with M/s. Minepro Communications for marketing services which include advertising and publicity. The ....